| Autor: |
Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T |
| Jazyk: |
angličtina |
| Zdroj: |
Atherosclerosis [Atherosclerosis] 1976 Sep; Vol. 24 (3), pp. 537-46. |
| DOI: |
10.1016/0021-9150(76)90146-5 |
| Abstrakt: |
A double-blind study comparing halofenate, a new lipid-lowering investigation drug, with an established drug, clofibrate, was conducted on 33 clinic patients with Type II hyperlipoproteinemia for a period of 48-96 weeks. All but 10 patients had some type of symptomatic major vascular disease. With respect to serum cholesterol levels, a comparable proportion (56-59%) of patients in each group responded to the respective treatment but the magnitude of lowering was substantially less for the halofenate responders (12% mean decrease versus 25%). Type IIa patients in both groups were more likely than Type IIb patients to have a favorable cholesterol-lowering response. Weight gain of 5% or greater was prejudicial to cholesterol lowering. In the case of serum triglycerides, the proportion of patients responding to clofibrate treatment was somewhat greater (87% versus 57% for halofenate) but the mean magnitude of lowering (27-34%) was comparable for responders in the two groups. Weight gain did not influence appreciably the triglyceride-lowering effect. Elevated concentrations of triglyceride (Type IIb) in the control period favored a triglyceride lowering response by clofibrate but was only a moderate influence on the response to halofenate. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
